Editorial · 30 Jan 2025
Short communicationPublished 16 Sep 2020
Differential effects of intraperitoneal and oral rotenone administration on Parkinson’s-disease-linked genes, brain urea levels and gut pathology in a rat model of Parkinson’s disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Parkinson’s disease (PD) is a progressive disease characterized by basal ganglia dysfunction caused by degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and development of fibrillar cytoplasmic inclusions that contain alpha synuclein (α-syn) and ubiquitin. Many pivotal works have plausibly linked autophagy and mitochondrial energy dysfunction with PD. In other neurodegenerative conditions, including Alzheimer’s disease (AD) and Huntington’s disease (HD), brain urea levels are elevated, although the relative cause for these changes is unknown. Several studies demonstrated that gut microbiota may contribute to PD, and these effects could increase α-syn expression in gut tissue. While there is ample evidence that emphasizes the importance of both brain and gut pathological changes in PD, there is no definitive proof as to which organ is affected first. Rodent rotenone models of PD have been widely employed to explore molecular mechanisms involved in thedisease pathogenesis and to test the efficacy of therapeutic drugs. However, it is unknown whether or not the impact of oral (po) and intraperitoneal (ip) rotenone promotes the same PD pathogenesis. To this end, we explored whether po and ip rotenone treatment induced a similar PD-like progression. We examined various protein and gene expression changes as well as urea levels in brain samples and the results indicate that sub chronic systemic rotenone administration altered α-syn and tyrosine hydroxylase levels in the corpus striatum, data that are indicative of rotenone-induced neuronal damage. Gene expression changes in autophagy- and energy-homeostasis-related genes as well as brain urea levels suggest the rotenone impairs normal cellular processes. Intriguingly, there were apparent differences between ip and po rotenone administration, where the former method more robustly affected these measures. Finally, the notable gut histopathology alteration induced by systemic rotenone administration implicates the gut microbiota and/or ENS in the PD-like pathology.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Dementia.
Editorial · 30 Jan 2025
Advances in Early Dementia Diagnosis: The Role of Imaging and Genetic Markers
Perspective · 30 Jan 2025
The Impact of Aging on Cognitive Function: Exploring Molecular Pathways and Interventions
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Dementia
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Suchitra Kavuri”